| Amount : | 5 mg |
| Content : | White Semi-Solid |
| Storage condition : | Store at -20°C |
Molecular Weight: 263Formula: C11H18FNO5Mass Spec: M+1=468.2TLC: Single-Spot (EtOAc: Hexane, 3.7) : Rf:0.5 NMR: All functional groups are present
SOLUBILITY:Prepare the stock solution of 20 mM in DMSO. Aliquot the stock solution and store it in -20°C
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
There are currently no product reviews Write a review on this product! |
Customers who purchased this product also purchased
Z-D(OMe)E(OMe)VD(OMe)-FMK (Cas...


Q-VD-OPH (Pan Caspase Inhibito...


Z-VAD (OMe)-FMK


CpG ODN (1668), TLR9 ligand (C...


CpG ODN (1826), TLR9 ligand (C...


CpG ODN (2006), TLR9 ligand (C...


Imidazoquinoline Resiquimod (R...


FSL-1


Flagellin


Lipopolysaccharide-LPS from Ec...


Poly(I).Poly(C), HMW


Pam3CSK4


Imiquimod, TLR7 ligand (4-Amin...


E-64d

Z-D(OMe)E(OMe)VD(OMe)-FMK (Cas...


Q-VD-OPH (Pan Caspase Inhibito...


Z-VAD (OMe)-FMK


CpG ODN (1668), TLR9 ligand (C...


CpG ODN (1826), TLR9 ligand (C...


CpG ODN (2006), TLR9 ligand (C...


Imidazoquinoline Resiquimod (R...


FSL-1


Flagellin


Lipopolysaccharide-LPS from Ec...


Poly(I).Poly(C), HMW


Pam3CSK4


Imiquimod, TLR7 ligand (4-Amin...


E-64d

Most viewed Products

Recombinant Human Thioredoxin-Like ...


Monoclonal antibody to Human PD-L1 ...


Monoclonal Antibody to Human IL-1be...


Monoclonal Antibody to Caspase-3 (P...


Polyclonal Antibody to Beta actin


Monoclonal Antibody to GAPDH (Clone...


Monoclonal antibody to B7-H4 (Clone...


Polyclonal Antibody to Beta Tubulin


NF-kB Leeporter™ Luciferase Repor...


Peroxidase conjugated Goat anti Mou...

ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他站友认领”
MaggotsFasterThanScalpelinWoundDebridement
December19,2011—Maggotdebridementtherapy(MDT)appearstobemoreeffectiveforwounddebridementcomparedwithconventionaltherapy,butonlyat1week;afterthattime,anothertypeofdressingshouldbeused,newresearchsuggests.
KristinaOpletalovà,MD,fromtheDepartmentofDermatology,UniversityofCaen,France,andcolleaguespublishedonlineDecember19intheArchivesofDermatology.
MedicalmaggotswereapprovedbytheUSFoodandDrugAdmiNISTrationasamedicaldeviceforwounddebridementin2004.Accordingtotheresearchers,useofmaggotsintreatingwoundsisassociatedwitheffectivewounddebridement,antibacterialeffects,andstimulationofwoundhealing.
However,theypointout,"[r]elativelyfewclinicalstudieshavebeenconductedandtheresultsarenotclear,partlyowingtomethodologicassessmentproblems."
InthecurrentProspective,randomizedcontrolled,phase3clinicaltrial,theresearcherssoughttodeterminetheefficacyofbaggedlarvaeonwounddebridementincomparisonwithconventionaltreatment.
TheprimaryobjectivewastocomparethemeanpercentageofsloughinwoundstreatedwithMDTwiththatofconventionaltreatmentatday15.Thestudyincluded119patientswithanonhealing,sloughywoundthatwas40cm2orsmallerandlessthan2cmdeep.Patientsalsohadananklebrachialindexof0.8orhigher.
Treatmentwasadministeredduringa2-weekhospitalstay.Conventionaltreatmentconsistedofsurgicaldebridement3timesaweekwithascalpel,withuseoftopicalanesthesia.TheMDTwasadministeredusinganencloseddressing(Vitapad,BioMondeLaboratories)containing80sterilemaggots.Atdischarge,aconventionaldressingwasapplied,andpatientswerefollowed-upatday30.
DebridementbyMDTwassignificantlyfasterthansurgicaldebridementduringthefirstweekoftreatment,reachingthesamelevelthecontrolgroupreachedatday15.NobenefitforMDTcomparedwithconventionaltreatmentinhealingrateswasobserved.Atday8,54.5%intheMDTgroupvs66.5%inthecontrolgroup(P=.04)hadevidenceofsloughandwoundhealing.However,byday15,themeanpercentageofsloughwas55.4%intheMDTgroupand53.8%inthecontrolgroup(P=.78).
"AthoughMDTshowsnosignificantbenefitatday15comparedwithconventionaltreatment,debridementbyMDTissignificantlyfasterandoccursduringthefirstweekoftreatment,"theresearchersconclude."Becausethereisnobenefitincontinuingthetreatmentafter1week,anothertypeofdressingshouldbeusedafter2or3applicationsofMDT."
Painscoresweresimilarandmildinbothgroups,althoughincontrasttoconventionaltreatment,MDTwasperformedwithouttopicalanesthesia.
Accordingtotheresearchers,noneofthepatientswerereticentaboutundergoingMDT."[A]crawlingsensationonthewoundwasrarelyandalmostequallynotedinbothgroups,revealingthatthesensationwassubjective,"Dr.Opletalovàandcolleaguespointout.
TwoquestionsregardingMDTremainunanswered,theauthorsnote."Candebridementbeimprovedusingmoremaggotsperdressing?Ifso,wouldthesedressingsbemorepainful?Furtherstudiesareneededtoanswerthesequestions."
ThestudywassupportedbygrantsfromtheClinicalResearchHospitalProgramandfromtheFrenchSocietyofDermatology.Theauthorshavedisclosednorelevantfinancialrelationships.
2.微孔板:选择实验所需的板条数。剩余不用的部分随同干燥剂密封放回原袋。 1.包被有抗抑制素bB亚单位抗体的微孔板(Anti-InhibinB-CoatedMicrotitrationStrips):96孔,2-8ºC下密封保存。
2.标准品A/样本稀释液(InhibinBStandardA/SampleDiluent):2ml×1瓶,胎牛血清,含0pg/mL二聚体抑制素B。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
3.标准品B-G(InhibinBStandardsB-G):1ml×6瓶,胎牛血清,含二聚体抑制素B的浓度为10,30,100,250,500,1000pg/mL。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
4.质控(InhibinBControls):1ml×2瓶,浓度I、II,胎牛血清,含低浓度和高浓度的抑制素A二聚体。使用前2-8ºC下保存。打开后2-8ºC下可保存2周。于-20ºC可长期保存。
5.样本稀释液A(InhibinBSampleBufferA):10ml×1瓶,2-8ºC下保存。
6.样本稀释液B(InhibinBSampleBufferB):10ml×1瓶,2-8ºC下保存。
7.抗体-生物素结合物(InhibinBAntibody-BiotinConjugate)(即用型):10ml×1瓶,含生物素标记的抗抑制素a亚单位抗体。2-8ºC下保存。
8.酶结合物(浓缩)(Streptavidin-EnzymeConjugate)(即用型):10ml×1瓶,含链霉和素-辣根过氧化物酶结合物。2-8ºC下保存。
9.TMB底物溶液(TMBChromogenSolution):15ml×1瓶,2-8ºC下保存。
10.终止液(StoppingSolution):15ml×1瓶,为0.2M的硫酸。2-8ºC下保存。
11.浓缩洗液(WashConcentrate):100ml×1瓶,2-8ºC下保存。 操作前所有试剂都应平衡至室温(~25ºC)并充分混匀。标准品、质控及待测样本需同时做双份。
1.取出实验所需板条,并记录各孔位置。
2.在对应的孔中加入标准品、质控及待测样本各50ul。
3.每孔加入25ul样本稀释液A。
4.每孔加入25ul样本稀释液B。
5.封板,以300-400rpm速度震荡,室温下过夜(14-18小时)。
6.洗板3次,在吸水纸上拍干。
7.每孔加入50ul抗体-生物素结合物。
8.封板,以500-700rpm速度震荡,室温下孵育1.5小时。
9.洗板6次,在吸水纸上拍干。
10.每孔加入50ul链霉和素-辣根过氧化物酶结合物。
11.封板,以500-700rpm速度震荡,室温下孵育20分钟。
12.洗板6次,洗完最后一次以后,将洗液在孔内停留15分钟再除去。在吸水纸上拍干。
13.在每孔中加入100ulTMB底物溶液。
14.以500-700rpm速度震荡,室温下避光孵育15-30分钟。
15.每孔加入100ul终止液。
16.30分钟内在450nm处读数。
注:必须以零标准作空白。如果能做到双波长测定,可在600或620nm处读数,将600(620)nm吸收值从450nm处减去,这样可以减少光学误差。 使用血清样本,静脉穿刺术采集血液。样本于2-8ºC可保存24小时,-20ºC或以下可保存30天。避免反复冻融样本。不应采用溶血或脂血的样本。冰冻的样本在实验前应解冻,并充分混匀。向左转|向右转
抑制剂刺激细胞后,需要用PBS清洗后再做后续实验吗
ajtr0009-1230.pdf(2384.3k)
我做的是细胞因子的刺激和抑制某条通路后观察是否有影响,分组为空白组,空白+抑制剂,刺激组,刺激+抑制剂,最开始用的单因素方差分析,LSD-T和SNK-Q检验,但是同学说我这里面有两个处理因素,所以不能单因素方差分析,应该直接空白和空白+抑制,空白和刺激,刺激和刺激+抑制剂进行独立样本T检验,现在脑子是混乱的,拜托园子里的大神们帮我看看,感激不尽!!
支原体培养则是取样后在培养基上培养,看有多少支原体菌落会长出,是比较直观和可信的结果。
总体来讲,这两种检查手段可信度都较高,结合一起,不仅可以可靠的知道有无解脲支原体感染,还能知道感染是否严重。
我用conA和LPS分别刺激脾细胞,当然细胞均有明显的增殖,可是如果把这两种有丝分裂原同时用来刺激细胞时,细胞的增殖明显受到了抑制,比起单独采用ConA或者LPS都低很多。conA和LPS分别刺激T细胞和B细胞的增殖,两者同时加入时,作用应该更强,为什么反而大幅减弱呢?
此外,我研究的这种成分单独刺激皮细胞时,细胞也有一定程度的增殖,但是如果这种物质与conA联合使用时,比起单独用conA时,细胞的增殖程度明显降低了一些,这又是什么原因呢?难道可以解释为我研究的这种物质有类似于LPS的作用——刺激B细胞增殖?
如果真的是这样来解释,哪位大侠能把第一个现象(conA和LPS共同作用产生拮抗)的机理帮我解释一下呢?

